Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Phase 2

Terminated

• Conditions: Major Depressive Disorder With Suicidal Ideation With Intent
• Interventions: Drug: MIJ821 Intravenous Injection; Drug: Placebo Intravenous Injection

• Registration Number: NCT04722666
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent

Detailed Description

The main purpose of this study is to support the dose selection for future Phase III clinical trials by evaluating efficacy and safety of four MIJ821 doses (very low, low, high and very high) administered every other week by intravenous infusion on top of pharmacological antidepressant treatment, compared with placebo, for the rapid reduction of the symptoms of MDD in participants who have suicidal ideation with intent. In addition, the study will explore the effect of single dose administration of very high and high doses to treat MDD in participants who have suicidal ideation with intent.

The study consists of three periods: a Screening Period (up to 48 hrs), a double-blind Core Period (6 weeks) and Extension Period (up to 52 weeks). The Extension Period will explore durability of the effect of the study treatment and the effect of MIJ821 on relapse rate, as well as safety of repeated MIJ821 administration.

All patients in the extension period will receive active treatment.

Study Timeline

• Study First Submitted: 2021-01-21
• Study First Submitted QC: 2021-01-21
• Study First Posted: 2021-01-25
• Study Start: 2021-07-20
• Primary Completion: 2023-09-26
• Study Completion: 2023-09-26
• Status Verified: 2023-10
• Last Update Submitted: 2024-04-19
• Last Update Posted: 2024-04-22

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Signed informed consent must be obtained prior to participation in the study
2. Male and female participants, 18 to 65 years of age (inclusive) at screening
3. DSM-5 defined major depressive disorder (MDD) with a current major depressive episode (MDE) without psychotic features at the time of screening based upon clinical assessment and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.) assessed at Screening
4. Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 AND either Question B10 or Question B11 obtained from the M.I.N.I., assessed at Screening
5. Current suicidal ideation with intent, confirmed by "Yes" response to Question 3 AND either Question 9 or Question 10 obtained from the SSTS at Baseline
6. Montgomery-Åsberg Depression Rating Scale (MADRS) score > 28 at Screening and before randomization on Day 1
7. Participants must agree to receive pharmacological standard of care treatment to treat their MDD (as determined by the treating physician(s) based on clinical judgement and local treatment guidelines) during the trial duration
8. In the physician's opinion, acute psychiatric hospitalization is clinically warranted to treat the patient's condition, and the patient is either already in the hospital or agrees to be hospitalized voluntarily for the required per protocol period

Read More

Exclusion Criteria

1. Any prior or current diagnosis of bipolar disorder, MDD with psychotic features, schizophrenia, or schizoaffective disorder as obtained from M.I.N.I. at Screening

2. Patients with acute alcohol or substance use disorder or withdrawal symptoms requiring detoxification, or patients who went through detoxification treatment (inpatient or outpatient) within 1 month before Screening.

3. Participant has a current clinical diagnosis of autism, dementia, or intellectual disability

4. History of seizures. Note: childhood febrile seizures are not exclusionary

5. Participants with borderline personality disorder as obtained from M.I.N.I. at Screening.

6. Participants with suicidal ideation or behavior caused primarily by another non-MDD condition as obtained from M.I.N.I. at Screening

7. Participants taking medications prohibited by the protocol

8. Intake of the following medications/ psychotherapy:

   1. Esketamine or Ketamine 2 months before Screening
   2. Monoamine oxidase inhibitors (MAOIs) 14 days before Screening
   3. Non-stable psychotherapy regimen and/or started less than 6 weeks before Screening

9. Any other condition (e.g. known liver disease/liver dysfunction, active malignancy, etc.) which in the opinion of the investigator would put the safety of the participant at risk, impede compliance or hinder completion of the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MIJ821 (mg/kg) - very low dose	MIJ821 Intravenous Injection	MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) - low dose	MIJ821 Intravenous Injection	MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821(mg/kg) - high dose	MIJ821 Intravenous Injection	MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) - very high dose	MIJ821 Intravenous Injection	MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
Placebo	Placebo Intravenous Injection	40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) - high dose/Placebo	MIJ821 Intravenous Injection	MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
MIJ821 (mg/kg) - high dose/Placebo	Placebo Intravenous Injection	MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
MIJ821 (mg/kg) - very high dose/Placebo	MIJ821 Intravenous Injection	MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
MIJ821 (mg/kg) - very high dose/Placebo	Placebo Intravenous Injection	MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29

Primary Outcome Measures

Name	Time	Method
Change from baseline in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS)	Baseline (first infusion) at 24 hours and up to 52 weeks	The Montgomery Åsberg Depression Rating Scale (MADRS, SIGMA version), is a clinician rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts and suicidal thoughts. The MADRS will be collected electronically by qualified personnel

Secondary Outcome Measures

Name	Time	Method
Percentage of participants meeting criteria for relapse in the Extension Period	From 6 weeks up to 52 weeks	Relapse for all patients meeting criteria for relapse over fixed period in the Extension Period
Number and severity of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI)	Baseline up to 6 weeks	Treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs) will be collected at all study visits
Pharmacokinetics (PK) of MIJ821 in plasma	Baseline up to 52 weeks	PK parameters of MIJ821 in plasma after 1st infusion described by AUClast, Cmax, Tmax and after each other infusion described by Cmax and Tmax. In order to better define the PK profile, the timing of the PK sample collection may be altered based on emergent data.
Percentage of participants meeting response criteria of ≥50% reduction	Baseline up to 6 weeks	Response criteria of ≥50% reduction from baseline in MADRS total score over time in the Core Period.
Percentage of participants meeting criteria for sustained response of ≥50% reduction	Baseline up to 6 weeks	Sustained response from baseline in MADRS total score for a period of at least four weeks in the Core Period
Percentage of participants meeting remission criteria of MADRS total score of ≤12	Baseline up to 6 weeks	Remission criteria of MADRS total score of ≤12 over time in the Core Period
Percentage of participants meeting sustained remission criteria of MADRS total score of ≤12	Baseline up to 6 weeks	Remission criteria of MADRS total score of ≤12 sustained for a period of at least four weeks in the Core Period
Percentage of relapsing participants meeting response criteria or remission criteria after the first infusion	From 6 weeks up to 52 weeks	Relapsing participants meeting response criteria or remission criteria after the first infusion of MIJ821 retreatment in the Extension Period

Trial Locations

Locations (1)

Novartis Investigative Site; 🇹🇷 Izmir, Turkey